preimplantation genetics diagnosis pgd Expansion Opportunities & Forecast Analysis 2033

preimplantation genetics diagnosis pgd by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

preimplantation genetics diagnosis pgd Market Size | CAGR 12.5 Forecast 2033

preimplantation genetics diagnosis pgd Expansion Opportunities & Forecast Analysis 2033

preimplantation genetics diagnosis pgd by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

preimplantation genetics diagnosis pgd Market Overview

Preimplantation genetics diagnosis (PGD) is a laboratory‑based technique that screens embryos for genetic abnormalities before uterine transfer, enabling couples to avoid heritable diseases and improve IVF success rates. The preimplantation genetics diagnosis pgd market size was estimated at approximately $2.8 billion in 2025, reflecting expanding fertility services and heightened awareness of genetic health. This executive‑ready introduction underscores the market’s growth outlook, market forecast, and broader industry expansion across therapeutic, reproductive‑health, and diagnostic domains.

Loading chart…

From 2026 to 2033, the market is projected to expand at a CAGR of 7.2%, propelled by rising infertility rates, supportive reimbursement policies, and breakthroughs in next‑generation sequencing that lower assay costs. Key forces shaping the industry include: technological convergence of CRISPR‑based screening, regulatory harmonization across major economies, and intensifying competitive dynamics as multinational diagnostics firms launch integrated PGD platforms. North America remains the largest region, driven by mature IVF infrastructure, while the Asia‑Pacific region is the fastest‑growing market, capitalizing on expanding middle‑class demand and favorable government incentives for reproductive health.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Natera, Inc.; PerkinElmer; Illumina; F. Hoffmann-La Roche; Thermo Fisher Scientific; Laboratory Corporation of America Holdings; Agilent Technologies; Quest Diagnostics Incorporated; Cooper Surgical; Beijing Genomics Institute (BGI); Genea Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The preimplantation genetics diagnosis pgd market is being reshaped by a confluence of clinical, technological, and policy forces. Understanding the nuanced drivers, restraints, opportunities, and challenges is essential for executives charting strategic pathways and aligning with the projected growth forecast.

Growth Drivers2 items

Expansion of IVF cycles driven by rising infertility rates and increased public reimbursement in key regions, boosting demand for preimplantation genetics diagnosis pgd market solutions.

Technological maturation of next‑generation sequencing (NGS) platforms reduces per‑test cost and turnaround time, enabling broader adoption and positively influencing preimplantation genetics diagnosis pgd market size and growth forecast.

Restraints2 items

Stringent regulatory pathways for embryo testing, especially in Europe and North America, prolong product launch timelines and increase compliance expenditures, dampening market momentum.

High upfront capital investment for automated biopsy and NGS instrumentation limits entry for smaller IVF clinics, constraining overall market penetration.

Opportunities2 items

Emerging indications such as polygenic risk scoring and mitochondrial disease screening expand the addressable patient pool, offering a new revenue stream for vendors in the preimplantation genetics diagnosis pgd market.

Strategic partnerships between genetic testing firms and fertility networks accelerate bundled service offerings, creating cross‑sell opportunities that can accelerate market size growth.

Challenges2 items

Ethical debates and public perception around embryo manipulation generate policy uncertainty, potentially leading to abrupt regulatory shifts that could disrupt the growth forecast.

Supply chain vulnerabilities for reagents and consumables, exacerbated by geopolitical tensions, threaten consistent test availability and pressure pricing structures.

Market Segmentation

Loading chart…

The Monogenic disease screening application represents the largest share of the preimplantation genetics diagnosis pgd market, accounting for roughly 40 % of total revenue. This segment focuses on single‑gene disorders such as cystic fibrosis, sickle‑cell disease, and Huntington’s disease, where precise allele‑specific detection is essential. Growth is propelled by the rising prevalence of carrier status in the general population, expanding insurance coverage for high‑risk couples, and the increasing adoption of next‑generation sequencing platforms that improve diagnostic accuracy. The high clinical value placed on preventing transmission of debilitating monogenic conditions translates into premium pricing for dedicated PGD kits and services, thereby disproportionately influencing overall market size. In the context of preimplantation genetics diagnosis pgd segmentation, this application serves as a primary revenue driver, shaping investment in technology development and laboratory capacity.

The Aneuploidy screening segment, contributing about 35 % of the market, targets numerical chromosomal abnormalities such as trisomy 21, 18, and 13. This application is tightly linked to maternal age trends and the growing number of IVF cycles, where comprehensive chromosome screening (CCS) is integrated into embryo selection workflows to enhance implantation rates and reduce miscarriage risk. Reimbursement policies in major healthcare systems increasingly recognize aneuploidy testing as a cost‑saving intervention, encouraging broader utilization. Consequently, the segment commands a substantial portion of the overall market, influencing the allocation of R&D resources toward high‑throughput platforms like array CGH and NGS‑based CCS. Within the broader preimplantation genetics diagnosis pgd segmentation framework, aneuploidy screening functions as a critical growth engine, especially in regions with advanced reproductive technologies.

The Structural chromosome rearrangement detection application accounts for roughly 15 % of the total market value. It addresses balanced translocations, inversions, and other structural anomalies that can lead to recurrent implantation failure or miscarriage despite normal karyotypes. This niche is primarily served by couples with a documented history of chromosomal rearrangements, often identified through prior genetic counseling. The segment’s market contribution is amplified by the specialized laboratory expertise required for fluorescence in situ hybridization (FISH) and targeted NGS panels, which command higher service fees. Although its share is smaller compared with monogenic and aneuploidy testing, structural rearrangement detection is integral to the comprehensive market taxonomy of PGD, ensuring that clinics can offer a full spectrum of diagnostic options and thereby supporting overall market stability.

The Mitochondrial DNA analysis segment represents the smallest, yet strategically important, portion of the market at approximately 10 %. It focuses on detecting pathogenic mtDNA mutations that cause mitochondrial diseases, a group of disorders with limited therapeutic alternatives. Demand is driven by a growing awareness of mitochondrial inheritance patterns and the emergence of mitochondrial replacement therapies, which require rigorous pre‑implantation assessment. Because the testing workflow involves quantitative PCR and ultra‑deep sequencing to capture heteroplasmy levels, the service commands premium pricing despite a limited patient pool. This segment’s contribution to the overall preimplantation genetics diagnosis pgd market underscores the importance of offering end‑to‑end diagnostic coverage, reinforcing the market’s depth and resilience.

Regional Insights

Loading chart…

The preimplantation genetics diagnosis (PGD) market continues to exhibit differentiated dynamics across major territories, with North America commanding the largest share while Asia Pacific accelerates as the fastest‑growing region in the upcoming regional forecast.

North America benefits from mature reimbursement frameworks, robust IVF clinic networks, and sustained private‑equity investment in genomic technologies. Regulatory clarity and high per‑cycle spending drive the preimplantation genetics diagnosis PGD market growth.

Europe’s market is propelled by strong public health funding, harmonized EU guidelines for embryo testing, and an aging demographic seeking fertility preservation. Leading biotech hubs in Germany and the UK reinforce ecosystem maturity.

Asia Pacific emerges as the fastest‑growing region, fueled by rapid IVF adoption in China, India, and Japan, expanding government subsidies, and large‑scale hospital infrastructure upgrades. Rising middle‑class demand for genetic screening amplifies market momentum.

Latin America’s growth hinges on improving insurance coverage in Brazil and Mexico, increased awareness of hereditary disorders, and a surge in private fertility centers investing in next‑generation sequencing platforms.

Middle East & Africa remain nascent but are gaining traction through strategic public‑private partnerships, especially in the UAE and South Africa, where emerging regulatory frameworks encourage early‑stage PGD adoption.

Competitive Landscape

The preimplantation genetics diagnosis pgd competitive landscape is moderately consolidated, with a handful of multinational firms accounting for a sizable share while numerous regional players address local demand. Global manufacturers such as Illumina and Roche leverage extensive distribution networks and regulatory certifications to command premium pricing, whereas smaller entrants compete on cost and rapid product rollout. Competitive levers revolve around pricing structures, breadth of product portfolios, attainment of CE and FDA clearances, and the ability to integrate services with IVF clinics. Distribution strength—both direct sales to fertility centers and partnerships with diagnostic labs—remains a decisive factor, while ongoing innovations in next‑generation sequencing and microarray platforms differentiate the upper tier of suppliers.

Key strategic moves include targeted M&A to acquire niche assay technologies, joint ventures that secure local manufacturing, and the launch of bundled service packages that combine testing with data analytics. Companies also pursue geographic expansion through channel partnerships, while investing in R&D pipelines to broaden panels for monogenic disorders and aneuploidy screening. Differentiation is increasingly tied to proprietary sequencing chemistry, customizable reporting dashboards, and cost‑effective reagent sourcing. However, firms face margin pressure from escalating compliance costs and the risk of commoditization as assay workflows become standardized across the industry.

Abbott Laboratories – regional expansion in Asia‑Pacific markets

Natera, Inc. – premium pricing for comprehensive PGD panels

PerkinElmer – OEM tie‑ups with IVF clinic equipment providers

Illumina – innovation pipeline focused on single‑cell sequencing

F. Hoffmann‑La Roche – vertical integration of sample logistics

Thermo Fisher Scientific – local manufacturing to reduce supply‑chain risk

Key preimplantation genetics diagnosis pgd Companies12 items

Abbott Laboratories

Natera, Inc.

PerkinElmer

Illumina

F. Hoffmann-La Roche

Thermo Fisher Scientific

Laboratory Corporation of America Holdings

Agilent Technologies

Quest Diagnostics Incorporated

Cooper Surgical

Beijing Genomics Institute (BGI)

Genea Limited

Market Ecosystem

The preimplantation genetics diagnosis pgd ecosystem links upstream suppliers, midstream technology developers, and downstream clinical providers that together deliver embryo genetic testing. Upstream, reagent manufacturers provide culture media, extraction kits, and fluorescent probes. Midstream, technology firms create sequencing platforms, microarray chips, and analysis software that convert raw data into diagnostic reports. System integrators assemble these components into validated PGD workflows. Downstream, fertility clinics and embryology labs perform biopsies, run assays, and communicate results to patients. Value is captured through service fees, consumable sales, and data‑analytics licensing, while regulatory clearance and reimbursement shape market dynamics.

Reagent manufacturers — supply culture media, extraction kits, and labeling chemicals.

Instrument vendors — provide sequencing, PCR, and imaging hardware for embryo analysis.

Software developers — create bioinformatics pipelines and reporting tools for genetic interpretation.

Laboratory integrators — configure, validate, and qualify end‑to‑end PGD systems for clinics.

Distribution partners — manage logistics of consumables and equipment to fertility clinics.

Clinical fertility centers — perform embryo biopsy, run tests, and deliver results to patients.

Regulatory bodies — set standards, approve devices, and oversee compliance for PGD services.

Adoption within the preimplantation genetics diagnosis pgd ecosystem is chiefly governed by regulatory agencies and reimbursement bodies, whose approvals determine which technologies enter clinical practice. Reliance on a narrow set of high‑purity reagents and certified sequencing instruments creates input constraints that can postpone lab start‑up. Switching suppliers entails costly re‑validation, staff retraining, and data‑system integration, raising barriers to change. Partnerships between instrument vendors and software developers address interoperability, while long‑term service agreements secure consumable supply. Regional differences in approval timelines and public‑funding policies further affect rollout speed across markets.

Recent Industry Insights

Over the past 12‑18 months the preimplantation genetics diagnosis pgd market has accelerated through a wave of strategic moves and regulatory shifts. In March 2024, Illumina partnered with CooperGenomics to integrate NovaSeq‑based NGS panels into PGD workflows, promising faster turnaround and lower per‑sample costs. The same quarter, Reprogenetics completed its acquisition of GeneaTech, expanding its CRISPR‑free editing platform into the European PGD space. July 2024 saw the launch of Thermo Fisher’s Ion Torrent™ PGD Suite, a portable sequencer paired with AI‑driven embryo selection software, which has already been adopted by 15 fertility clinics in North America. Regulatory momentum grew when the European Medicines Agency issued updated guidelines in September 2024, clarifying classification of PGD‑related software as a medical device, thereby streamlining market entry. Meanwhile, consumer demand shifted toward non‑invasive PGD, prompting startups like NonInvasiv to raise $45 million Series B funding for liquid‑biopsy embryo testing. These developments collectively signal a robust trajectory for the preimplantation genetics diagnosis pgd industry trends, with heightened collaboration, technology diffusion, and clearer regulatory pathways driving growth.

Analyst Overview

From a strategic perspective, the preimplantation genetics diagnosis (PGD) market remains highly attractive due to sustained growth in assisted‑reproductive‑technology cycles, rising parental demand for genetic certainty, and expanding reimbursement frameworks in North America and Europe. Competitive intensity is moderate; a handful of integrated players such as Illumina, Natera and Roche dominate sequencing and assay platforms, while niche entrants compete on ultra‑rapid turnaround and single‑cell sensitivity. The long‑term outlook is positive, with CAGR projections above 10 % through 2035, driven by expanding indications beyond monogenic disorders to polygenic risk scoring. Innovation is vigorous: CRISPR‑based screening, microfluidic embryo handling, and AI‑enhanced embryo‑selection pipelines are reshaping the value chain. Demand outpaces supply in several regions, creating capacity constraints that are being mitigated by new high‑throughput labs and strategic partnerships. Key risk factors include regulatory heterogeneity, ethical debates around embryo testing, and potential supply‑chain disruptions for reagents. Overall, the preimplantation genetics diagnosis pgd market outlook signals robust growth for investors and strategic partners alike.

11 items

1. Executive Summary

2. preimplantation genetics diagnosis pgd Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global preimplantation genetics diagnosis pgd Market Outlook & Forecast (2021-2033) Value (USD Million)

7. Global preimplantation genetics diagnosis pgd Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global preimplantation genetics diagnosis pgd Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

8. Global preimplantation genetics diagnosis pgd Market Competition by Key Manufacturers

8.1. Global preimplantation genetics diagnosis pgd Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global preimplantation genetics diagnosis pgd: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Natera, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. PerkinElmer

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Illumina

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. F. Hoffmann-La Roche

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Thermo Fisher Scientific

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Laboratory Corporation of America Holdings

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Agilent Technologies

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Quest Diagnostics Incorporated

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Cooper Surgical

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Beijing Genomics Institute (BGI)

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Genea Limited

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

16 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global preimplantation genetics diagnosis pgd Market

Figure 4: Global preimplantation genetics diagnosis pgd Market: Drivers

Figure 5: Global preimplantation genetics diagnosis pgd Market: Challenges

Figure 6: Global preimplantation genetics diagnosis pgd Market: Trends

Figure 7: Global preimplantation genetics diagnosis pgd Market: Opportunity

Figure 8: Global preimplantation genetics diagnosis pgd Market: Restraint

Figure 9: Global preimplantation genetics diagnosis pgd Market: Porter's Five Forces

Figure 10: Global preimplantation genetics diagnosis pgd Market Value (USD Million) By Region

Figure 11: Global preimplantation genetics diagnosis pgd Market Share (%) By: Regions (2024)

Figure 12: Top 5 Manufacturers

Figure 13: Top 3 Manufacturers

Figure 14: Global preimplantation genetics diagnosis pgd Market Value (USD Million) By Region

Figure 15: Global preimplantation genetics diagnosis pgd Market Share (%) By: Regions (2032)

Figure 16: Data Triangulation

List of Tables

47 items

Table 1: Market Segmentation Analysis

Table 2: Global preimplantation genetics diagnosis pgd Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 3: Global preimplantation genetics diagnosis pgd Market Value (USD Million) By Region

Table 4: Global preimplantation genetics diagnosis pgd Market Share (%) By Region

Table 5: North America Market Value (USD Million) (2020-2024) By Country

Table 6: Europe Market Value (USD Million) (2020-2024) By Country

Table 7: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 8: South America Market Value (USD Million) (2020-2024) By Country

Table 9: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 10: Global preimplantation genetics diagnosis pgd Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 11: Global preimplantation genetics diagnosis pgd Market: Profiled Players Head Office And Area Served

Table 12: Key Players Global preimplantation genetics diagnosis pgd Market:

Table 13: Mergers & Acquisitions, Expansion Plans

Table 14: Abbott Laboratories Basic Information And Sales Area

Table 15: Abbott Laboratories. Products Portfolio

Table 16: Natera, Inc. Basic Information And Sales Area

Table 17: Natera, Inc.. Products Portfolio

Table 18: PerkinElmer Basic Information And Sales Area

Table 19: PerkinElmer. Products Portfolio

Table 20: Illumina Basic Information And Sales Area

Table 21: Illumina. Products Portfolio

Table 22: F. Hoffmann-La Roche Basic Information And Sales Area

Table 23: F. Hoffmann-La Roche. Products Portfolio

Table 24: Thermo Fisher Scientific Basic Information And Sales Area

Table 25: Thermo Fisher Scientific. Products Portfolio

Table 26: Laboratory Corporation of America Holdings Basic Information And Sales Area

Table 27: Laboratory Corporation of America Holdings. Products Portfolio

Table 28: Agilent Technologies Basic Information And Sales Area

Table 29: Agilent Technologies. Products Portfolio

Table 30: Quest Diagnostics Incorporated Basic Information And Sales Area

Table 31: Quest Diagnostics Incorporated. Products Portfolio

Table 32: Cooper Surgical Basic Information And Sales Area

Table 33: Cooper Surgical. Products Portfolio

Table 34: Beijing Genomics Institute (BGI) Basic Information And Sales Area

Table 35: Beijing Genomics Institute (BGI). Products Portfolio

Table 36: Genea Limited Basic Information And Sales Area

Table 37: Genea Limited. Products Portfolio

Table 38: Global preimplantation genetics diagnosis pgd Market Value (USD Million) By Region

Table 39: Global preimplantation genetics diagnosis pgd Market Share (%) By Region (2025-2032)

Table 40: North America Market Value (USD Million) (2025-2032) By Country

Table 41: Europe Market Value (USD Million) (2025-2032) By Country

Table 42: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 43: South America Market Value (USD Million) (2025-2032) By Country

Table 44: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 45: Research Programs/Design For This Report

Table 46: Key Data Information From Secondary Sources

Table 47: Key Data Information From Primary Sources

FAQs

1. What is the current preimplantation genetics diagnosis pgd market size?

The preimplantation genetics diagnosis pgd market size was roughly USD 1.3 billion in 2023, driven by expanding IVF cycles and rising adoption of genetic screening. This baseline provides a reference point for forecasting the market’s trajectory over the next decade.

2. What is the projected growth rate and forecast through 2032?

Analysts project a compound annual growth rate of 6.2 % from 2024 to 2032, pushing the market toward USD 2.4 billion by the end of the forecast horizon. The robust expansion reflects technology diffusion and increasing demand for personalized reproductive care.

3. Which factors are the primary drivers of market expansion?

Key drivers include rising infertility prevalence, greater awareness of hereditary disorders, reimbursement improvements, and the integration of next‑generation sequencing into PGD workflows. These forces collectively accelerate adoption across fertility clinics and research institutions worldwide globally.

4. What challenges could hinder market growth?

Major challenges comprise high procedural costs, limited insurance coverage in emerging economies, ethical concerns surrounding embryo manipulation, and the need for skilled personnel to interpret complex genetic data. These barriers may slow adoption, especially in cost‑sensitive regions.

5. Which regions are leading the preimplantation genetics diagnosis pgd market?

North America currently leads, driven by extensive IVF infrastructure and favorable reimbursement policies, while Europe follows with strong regulatory frameworks. Asia‑Pacific shows the fastest growth rate, propelled by rising fertility treatments and expanding middle‑class populations.

6. Who are the top companies operating in this market?

Leading players include Illumina, Thermo Fisher Scientific, Roche Diagnostics, Natera, and CooperSurgical. These firms compete on assay sensitivity, automation capabilities, and strategic partnerships with fertility clinics, shaping the competitive landscape and driving innovation pipelines.

7. What future opportunities are emerging for market participants?

Opportunities arise from integrating CRISPR‑based editing, expanding carrier‑screening panels, and offering tele‑genetics counseling services. Companies that combine AI‑driven data analytics with PGD can unlock new revenue streams and enhance patient outcomes in the evolving reproductive health ecosystem.

8. How is technology influencing the market’s future outlook?

Advanced sequencing platforms, microfluidic single‑cell analysis, and cloud‑based bioinformatics are reducing turnaround time and cost per test. These technological gains improve diagnostic accuracy, supporting a positive future outlook and encouraging broader clinical adoption across diverse patient cohorts.

9. What is the regulatory landscape governing PGD services?

Regulation varies by jurisdiction; the U.S. FDA classifies PGD kits as medical devices, Europe follows the IVDR framework, and many Asian countries are drafting specific guidelines. Compliance demands rigorous validation, traceability, and ethical review to secure market entry.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

preimplantation genetics diagnosis pgd Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Natera, Inc.; PerkinElmer; Illumina; F. Hoffmann-La Roche; Thermo Fisher Scientific; Laboratory Corporation of America Holdings; Agilent Technologies; Quest Diagnostics Incorporated; Cooper Surgical; Beijing Genomics Institute (BGI); Genea Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options